UOC
LRMR icon

UBS O'Connor’s Larimar Therapeutics LRMR Stock Holding History

UBS O'Connor’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-307,198
Closed -$888K – 384
2025
Q2 		$888K Buy
307,198
+127,171
+71% +$294K 0.02% 237
2025
Q1 		$387K Sell
180,027
-8,516
-5% -$26.9K 0.01% 230
2024
Q4 		$730K Sell
188,543
-14,240
-7% -$94K 0.02% 256
2024
Q3 		$1.33M Sell
202,783
-5,000
-2% -$40.2K 0.03% 244
2024
Q2 		$1.51M Buy
207,783
+5,000
+2% +$38.3K 0.04% 235
2024
Q1 		$1.54M Sell
202,783
-117,118
-37% -$913K 0.04% 229
2023
Q4 		$1.46M Sell
319,901
-58,604
-15% -$198K 0.05% 223
2023
Q3 		$1.5M Buy
378,505
+15,000
+4% +$56.7K 0.03% 286
2023
Q2 		$1.14M Buy
363,505
+151,011
+71% +$616K 0.02% 370
2023
Q1 		$963K Buy
212,494
+53,082
+33% +$277K 0.02% 409
2022
Q4 		$658K Buy
+159,412
New +$544K 0.01% 600
2015
Q3 		– Sell
-13,367
Closed -$5.55M – 663
2015
Q2 		$5.55M Buy
13,367
+6,700
+100% +$2.8M 0.05% 319
2015
Q1 		$3.17M Buy
+6,667
New +$3.16M 0.03% 340

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

UBS O'Connor's LRMR Position: Q3 2025 in Review

UBS O'Connor sold out of Larimar Therapeutics (LRMR) in Q3 2025, closing a stake of 307,198 shares — an estimated $888K sold.

UBS O'Connor first reported a position in LRMR in Q1 2015 and held it in 13 quarters. The position peaked at $5.55M in Q2 2015. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

  • UBS O'Connor reported no remaining Larimar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 307,198 Larimar Therapeutics shares in Q3 2025, an estimated $888K.
  • UBS O'Connor first reported a position in Larimar Therapeutics in Q1 2015 and held it in 13 quarters.
  • UBS O'Connor's Larimar Therapeutics position peaked at $5.55M in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.